Trust Signals
Key Takeaways
- CJC-1295 (with DAC) extended its half-life to approximately 6 to 8 days via albumin binding in Teichman et al. (2006), producing sustained IGF-1 elevations of roughly 30 to 70 percent above baseline in a 28-subject phase II trial.
- Sermorelin's half-life is roughly 10 to 20 minutes, meaning it produces brief, physiologic-style GH pulses rather than sustained elevation, which many clinicians consider a safety advantage.
- No published human RCT has studied CJC-1295 and ipamorelin as a co-administered pair; the combination rationale is mechanistic, not trial-proven.
- Sermorelin was FDA-approved (as Geref) and withdrawn in 2008 for commercial reasons, not safety findings, giving it the strongest historical regulatory record of the three compounds.
- Ipamorelin's selectivity for GH release with minimal effect on cortisol or prolactin is supported by animal pharmacology studies; long-term controlled human data remain sparse.
Direct Answer: CJC Ipamorelin vs Sermorelin
Table of Contents
- How Does Each Compound Work at the Receptor Level?
- What Does the Evidence Actually Show? (Evidence Ledger)
- What Do the Numbers Mean? Mechanism with Real Data
- What Most Pages Get Wrong About This Comparison
- Honest Head-to-Head Table: CJC/Ipamorelin vs Sermorelin
- Why Does the DAC Modification Change Everything? (Chemistry Behind the Rule)
- Dosing, Timing, and Operational Protocols
- How to Read a COA and Spot a Degraded Product
- Side Effects and Safety: What the Data Actually Says
- Regulatory and Doping Status
- FAQ
- Sources
How Does Each Compound Work at the Receptor Level?
Three separate compounds are involved in this comparison, and treating them as a single entity is a common error.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Sermorelin is a synthetic analog of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH 1-29). It binds the GHRH receptor (GHRHR) on anterior pituitary somatotroph cells, activating adenylyl cyclase through Gs protein coupling, raising intracellular cAMP, and triggering GH synthesis and secretion. Because it mirrors the body's own GHRH signal, it preserves the hypothalamic-pituitary feedback loop.
CJC-1295 is also a GHRH analog, but with four amino acid substitutions relative to GHRH 1-29 (at positions 2, 8, 15, and 27 in the Modified GRF 1-29 sequence) that resist enzymatic cleavage by dipeptidyl peptidase IV and other proteases. The DAC version adds a maleimide-lysine modification at the C-terminus that allows irreversible binding to cysteine-34 of serum albumin after injection, dramatically extending circulating half-life. Without DAC, it is functionally similar to sermorelin but with modestly improved proteolytic stability.
Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts as a selective agonist at the ghrelin receptor, also called growth hormone secretagogue receptor 1a (GHSR-1a). This is an entirely different receptor from GHRHR. GHSR-1a couples through Gq, raising intracellular calcium and activating protein kinase C, leading to GH release by a distinct intracellular cascade. Critically, when a GHRH analog and a GHSR agonist are combined, the two pathways show synergistic GH release that exceeds either agent alone, a principle established in animal pharmacology and extrapolated to clinical compounding practice.
What Does the Evidence Actually Show? (Evidence Ledger)
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| Sermorelin increases GH and IGF-1 in GH-deficient adults | Human RCTs, FDA review data (pre-2008) | Positive | High |
| CJC-1295 (with DAC) raises IGF-1 by roughly 30 to 70% above baseline | Phase II human RCT, Teichman et al. (2006), n=28 | Positive | Moderate (single small trial) |
| Ipamorelin selectively stimulates GH with minimal cortisol or prolactin rise | Animal (rat, swine) pharmacology studies; limited early human pharmacokinetic data | Positive for selectivity | Low for humans (animal data predominate) |
| CJC-1295 plus ipamorelin combination is superior to either alone | Mechanistic rationale, no human RCT | Directionally positive (theoretical) | Very Low |
| Sermorelin improves body composition in adults over 40 | Small open-label human studies, not powered RCTs | Modest positive trend | Low |
| GH secretagogues improve sleep quality | Mechanistic (GH pulse coincides with slow-wave sleep), small human data | Positive trend | Low |
| Long-term safety of compounded CJC-1295/ipamorelin in humans | No controlled long-term data; case reports and prescriber series only | Unknown | Very Low |
What Do the Numbers Mean? Mechanism with Real Data
Teichman et al. (2006), published in the Journal of Clinical Endocrinology and Metabolism, enrolled healthy adults aged 21 to 61 years (n=28 for the key multiple-dose cohort). Subjects received CJC-1295 with DAC by subcutaneous injection once or twice weekly. At doses of 30 to 60 mcg/kg, mean IGF-1 levels increased by approximately 30 to 70 percent above baseline and remained elevated for 14 days after the last injection. Mean GH levels were elevated for 6 days after a single dose.
What that does NOT prove: elevated IGF-1 for two weeks is not physiologic. Human GH is secreted in pulses, typically 6 to 12 per day, with the largest pulse occurring in the first hour of slow-wave sleep. Sustained IGF-1 elevation from a long-acting GHRH analog flattens this architecture. Whether flattening the pulse pattern has adverse effects on insulin sensitivity or receptor downregulation over years is not established in this or any subsequent trial.
Ipamorelin's selectivity profile is one of the most frequently cited reasons to prefer it over older GHRPs like GHRP-6 or GHRP-2. Animal pharmacology studies, primarily in rats and swine, showed that at equipotent GH-releasing doses, ipamorelin produced no statistically significant rise in ACTH or cortisol, while GHRP-6 produced a meaningful cortisol elevation. This selectivity distinction is supported in the peer-reviewed animal literature. However, the mechanistic reason (ipamorelin does not appear to activate CRH or AVP pathways at GH-releasing doses) applies directly to those animal models. Human equivalence is plausible but not formally demonstrated at scale in controlled trials.
Sermorelin's half-life of roughly 10 to 20 minutes in plasma (based on pharmacokinetic data from the original Geref NDA studies) means that a bedtime injection produces a GH pulse that mirrors the natural nocturnal surge. This brief window of stimulation is the core of the physiologic-pulse argument for sermorelin over longer-acting options.
What Most Pages Get Wrong About This Comparison
Almost every article comparing these compounds omits three things that matter clinically.
1. CJC-1295 without DAC and CJC-1295 with DAC are functionally different drugs. Most compounding prescriptions today use CJC-1295 without DAC (Modified GRF 1-29), which has a half-life closer to 30 minutes and produces a pulse, not a sustained plateau. When you see "CJC-1295/ipamorelin" in a compounding prescription, it almost always means the non-DAC version. The Teichman 2006 trial that generates all those IGF-1 percentage figures used the DAC version. Applying those numbers to the non-DAC product is an error. The non-DAC version has no published dose-finding RCT of its own.
2. Reconstituted peptide solutions degrade quickly and measurably. Peptide stability after reconstitution is not a minor footnote. Studies on GHRH-analog degradation in solution show that temperature excursions, repeated freeze-thaw cycles, and light exposure all accelerate hydrolysis and oxidation. A compounded vial sitting at room temperature loses potency faster than the label implies. This is not theoretical: it is the reason bacteriostatic water is used (the benzyl alcohol slows microbial growth, not chemical degradation) and why refrigerated storage at 2 to 8 degrees Celsius is mandatory, not optional.
3. Purity and concentration in compounded products are not guaranteed. Compounding pharmacies operating under 503A (patient-specific) or 503B (outsourcing) frameworks in the United States are inspected, but peptide assay and purity standards for GH secretagogues are not as tightly codified as for small-molecule drugs. Third-party testing of compounded peptides has, on multiple occasions across investigative reports, found concentrations meaningfully different from labeled amounts. When evaluating any compounded peptide, a certificate of analysis (COA) from an independent lab, not the manufacturer's own QC, is the relevant document.
Honest Head-to-Head Table: CJC/Ipamorelin vs Sermorelin
| Attribute | CJC-1295 (no DAC) + Ipamorelin | Sermorelin | Winner / Note |
|---|---|---|---|
| Receptor pathways targeted | GHRHR + GHSR-1a (dual) | GHRHR only | CJC/Ipamorelin (mechanistic advantage) |
| Half-life (non-DAC) | ~30 min (CJC); ipamorelin half-life estimated at roughly 2 hours in animal models | ~10 to 20 min | Tie; both produce pulse-like kinetics |
| Strength of human evidence | Weak (no combination RCT; CJC alone has one small trial) | Moderate (FDA approval history, multiple studies) | Sermorelin wins clearly |
| Physiologic pulse preservation | Good with no-DAC version; poor with DAC version | Good | Tie (no-DAC) or Sermorelin (DAC) |
| Cortisol/prolactin effect | Ipamorelin is highly selective in animal models; GHRH component minimal effect | Minimal | Tie |
| Dosing frequency | 1 to 3x daily (no-DAC); 1 to 2x weekly (DAC) | Once daily at bedtime | Sermorelin (simpler) |
| FDA regulatory history | Never approved | Approved 1997, withdrawn 2008 (commercial) | Sermorelin wins |
| Cost (compounded, typical) | Higher (two peptides, often higher dose volume) | Lower | Sermorelin wins |
| Theoretical GH output | Greater (dual-pathway synergy) | Moderate | CJC/Ipamorelin (mechanistic, unproven in humans) |
| Long-term safety data | None controlled | Limited but exists | Sermorelin wins by default |
Why Does the DAC Modification Change Everything? (Chemistry Behind the Rule)
The Drug Affinity Complex modification on CJC-1295 is a maleimide group attached to a lysine residue at the C-terminus of the peptide. After subcutaneous injection, the maleimide undergoes a thiol-Michael addition reaction with the free sulfhydryl group on cysteine-34 of circulating serum albumin. This reaction is rapid, essentially irreversible under physiologic pH and temperature, and creates an albumin-peptide conjugate that evades renal filtration (albumin is too large to pass the glomerulus at roughly 69 kDa) and resists proteolytic degradation.
The consequence: the peptide circulates for days rather than minutes. This is why the "store cold" rule matters especially for the DAC version. The maleimide group is susceptible to hydrolysis, which opens the maleimide ring and destroys its ability to bond albumin before injection. Hydrolysis accelerates at higher temperatures and in aqueous solution. A DAC-version vial left at room temperature for extended periods may reconstitute fine and look identical, but the functional albumin-binding capacity will be reduced. You cannot tell by appearance. This is the formulation gotcha that no medspa blog mentions.
For the non-DAC version, the amino acid substitutions (particularly at positions 2 and 8 in the Modified GRF 1-29 sequence) block dipeptidyl peptidase IV cleavage at the Pro-position that inactivates native GHRH within minutes. The result is a modestly longer half-life than sermorelin, perhaps 20 to 30 minutes versus 10 to 20 minutes, not the days-long extension of the DAC version. This is a difference in degree, not kind, compared to sermorelin.
Dosing, Timing, and Operational Protocols
| Compound | Common Compounded Dose | Frequency | Timing Rationale | Units |
|---|---|---|---|---|
| Sermorelin | 200 to 500 mcg | Once daily | Bedtime (amplifies nocturnal GH pulse) | mcg subcutaneous |
| CJC-1295 (no DAC) | 100 to 300 mcg per dose | 1 to 3x daily | Fasted state, bedtime preferred | mcg subcutaneous |
| Ipamorelin | 100 to 300 mcg per dose | 1 to 3x daily | Paired with CJC, fasted | mcg subcutaneous |
| CJC-1295 (with DAC) | 1,000 to 2,000 mcg | 1 to 2x weekly | Day of week is flexible; subcutaneous | mcg subcutaneous |
Dosing should always be individualized by the prescribing clinician. Food, especially carbohydrates and fats, blunts GH release by raising somatostatin tone. Injecting within 30 to 60 minutes of a meal reduces efficacy for all GH secretagogues. This is established physiology, not brand-specific advice.
How to Read a COA and Spot a Degraded Product
When receiving any compounded GH secretagogue, ask the pharmacy for the certificate of analysis from the testing laboratory (not the pharmacy's own internal test). The COA should report: peptide identity confirmed by HPLC or LC-MS, purity percentage (greater than 98 percent is the conventional standard for research-grade and compounded peptides), concentration in the final solution (should match label claim within roughly 10 percent for a reputable 503B facility), and absence of common impurities including acetate salts above threshold, residual solvents, and microbial contamination.
A degraded reconstituted solution may appear cloudy, have particulates, or show a color change (yellowing) in peptides prone to oxidation, though many degraded solutions appear visually identical to intact ones. The only reliable way to confirm potency is assay. If a vial has been temperature-abused or is past the beyond-use date, discard it. The risk of injecting a degraded peptide is not primarily toxicity but rather loss of therapeutic effect and, in the case of aggregated peptides, potential immunogenicity, a risk documented for aggregated protein therapeutics generally.
Side Effects and Safety: What the Data Actually Says
In Teichman et al. (2006), the most common adverse events with CJC-1295 (DAC) were injection site reactions (redness, pain) and headache, both described as mild and transient. No serious adverse events were attributed to the study drug in that small cohort.
Sermorelin's historical clinical trial data (available in summary form through FDA archives for the Geref NDA) showed similar tolerability: injection site reactions, flushing, and headache as the most frequent complaints. The FDA did not withdraw Geref for safety concerns.
Water retention is commonly reported by users of GH secretagogues and is expected from GH's physiologic effect on renal sodium handling. This is not a sign of pathology in most cases but can be uncomfortable. Transient glucose elevation is a theoretical concern with prolonged IGF-1 elevation, as GH is counter-regulatory to insulin; periodic fasting glucose and HbA1c monitoring is reasonable in longer-term protocols.
The often-repeated claim that ipamorelin "never raises cortisol" overstates the available data. Animal pharmacology studies showed no statistically significant cortisol elevation at GH-releasing doses, which is a meaningful distinction from GHRP-6. However, this does not mean zero cortisol effect is guaranteed in every human at every dose, and controlled human data at scale are absent.
Regulatory and Doping Status
In the United States, CJC-1295 and ipamorelin are not approved drugs. They are available as compounded preparations from licensed pharmacies when prescribed by a licensed practitioner for a specific patient (503A) or in larger volumes from FDA-registered outsourcing facilities (503B). The FDA has issued guidance documents and warning letters to compounding pharmacies related to peptides, and the regulatory environment for compounded GH secretagogues is subject to ongoing change. Patients and prescribers should verify current status.
Sermorelin is currently available as a compounded medication in the United States following the 2008 commercial withdrawal of Geref. It is not on the FDA's list of bulk drug substances that may not be compounded, as of the time of this writing, but that list is periodically updated.
WADA prohibits all GHRH analogs and GH secretagogue receptor agonists under Section 2 of the Prohibited List (Peptide Hormones, Growth Factors, Related Substances and Mimetics). This prohibition applies in and out of competition. Athletes subject to anti-doping testing should treat all three compounds as prohibited.
FAQ
What is the main difference between CJC-1295/ipamorelin and sermorelin?
Sermorelin is a GHRH analog (29 amino acids) that stimulates natural GH pulses via one receptor pathway. CJC-1295 with ipamorelin combines a GHRH analog with a GHSR agonist, activating two complementary pathways simultaneously and producing larger, more sustained GH elevations than sermorelin alone.
Which produces more growth hormone: CJC-1295/ipamorelin or sermorelin?
In head-to-head pharmacokinetic terms, CJC-1295 alone (with DAC) produced sustained IGF-1 elevations of roughly 30 to 70 percent above baseline lasting days in Teichman et al. (2006). Sermorelin produces a shorter GH pulse. The combination with ipamorelin adds synergistic GHSR stimulation, making the net GH output larger than sermorelin, though direct RCT comparisons against sermorelin are absent.
Is sermorelin safer than CJC-1295/ipamorelin?
Sermorelin has a longer clinical history, including FDA approval (withdrawn for commercial reasons in 2008, not safety). Its shorter half-life means GH pulses are brief and more physiologic. CJC-1295 with DAC creates prolonged GH elevations that may blunt the natural pulsatile pattern. Ipamorelin is considered selective among GHSRs with minimal cortisol or prolactin effect in animal studies, but long-term human safety data for the combination is limited.
What does DAC mean in CJC-1295 with DAC, and why does it matter?
DAC stands for Drug Affinity Complex, a maleimide-lysine modification that allows CJC-1295 to covalently bind albumin in vivo, extending its half-life from roughly 30 minutes (without DAC) to approximately 6 to 8 days. This long half-life creates near-continuous GH stimulation rather than physiologic pulses, which is a meaningful clinical distinction from sermorelin.
What is the standard dosing protocol for CJC-1295/ipamorelin versus sermorelin?
Sermorelin is typically dosed at 200 to 500 mcg subcutaneously at bedtime to align with the natural nocturnal GH pulse. CJC-1295 without DAC combined with ipamorelin is commonly used at 100 to 300 mcg of each peptide, one to three times daily, also preferably fasted and near bedtime. These are compounded medication protocols; doses vary by prescriber.
Do either of these peptides have FDA approval?
Sermorelin had FDA approval as Geref for GH deficiency in children; that approval was withdrawn in 2008 for commercial, not safety, reasons. CJC-1295 and ipamorelin are not FDA-approved drugs. Both are compounded by licensed pharmacies under a prescriber's order in the United States, with regulatory status subject to ongoing FDA oversight of the compounding industry.
How should CJC-1295/ipamorelin and sermorelin be stored?
Lyophilized (powder) forms of both should be stored at 2 to 8 degrees Celsius (refrigerated) and protected from light. After reconstitution with bacteriostatic water, solutions should be refrigerated and used within 28 to 30 days per standard compounding guidelines. Repeated freeze-thaw cycles degrade peptide bonds and reduce potency.
Can CJC-1295/ipamorelin or sermorelin be detected in sports drug testing?
Yes. Both peptide classes are prohibited by WADA under the category of peptide hormones, growth factors, and related substances. WADA has developed detection methods for GH-releasing peptides and GHRH analogs in urine and blood. Athletes subject to anti-doping rules should treat both as banned.
What are the most common side effects of CJC-1295/ipamorelin versus sermorelin?
Sermorelin side effects in clinical trials included injection site reactions, facial flushing, and headache. CJC-1295 clinical data (Teichman et al.) noted injection site reactions and headache. Ipamorelin animal studies show minimal cortisol or prolactin elevation compared to other GHRPs. Water retention and transient fatigue are commonly reported by users of all three compounds.
Why do most compounding prescriptions use CJC-1295 without DAC instead of with DAC?
CJC-1295 without DAC (also called Modified GRF 1-29) has a half-life of roughly 30 minutes, producing a pulse-like GH release similar to physiologic patterns. Many clinicians prefer this to the near-continuous stimulation of the DAC version, believing pulsatility better preserves receptor sensitivity and more closely mimics natural physiology.
Is there human RCT evidence for the CJC-1295/ipamorelin combination specifically?
No published RCT has studied the CJC-1295/ipamorelin combination as a co-administered pair in humans. Evidence for CJC-1295 exists from Teichman et al. (2006). Ipamorelin's selectivity profile is supported by animal pharmacology studies; early human pharmacokinetic data exist but are limited in scale. The combination rationale is mechanistic and pharmacologic, not RCT-proven.
Sources
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805.
- Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging. 2006;1(4):307-308.
- Frohman LA, Jansson JO. Growth hormone-releasing hormone. Endocrine Reviews. 1986;7(3):223-253.
- Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-977. (Foundational GHSR cloning study.)
- FDA. Geref (sermorelin acetate) product history and withdrawal notice. FDA Drug Databases, 2008. Available via FDA Orange Book historical records.
- World Anti-Doping Agency. Prohibited List 2024. WADA, 2024. Available at: wada-ama.org.
- Smith RG. Development of growth hormone secretagogues. Endocrine Reviews. 2005;26(3):346-360.
- Bowers CY. History of the discovery of growth hormone releasing peptides. Endocrine. 2012;41(1):13-21.
- US Pharmacopeia. General Chapter 797: Pharmaceutical Compounding, Sterile Preparations. USP-NF, current edition.